Health & Fitness
Health and Fitness
Health and Fitness 
Tue, May 15, 2012
Mon, May 14, 2012
Sun, May 13, 2012
Sat, May 12, 2012
Fri, May 11, 2012
Thu, May 10, 2012
Wed, May 9, 2012
Tue, May 8, 2012
Mon, May 7, 2012
Sat, May 5, 2012
Fri, May 4, 2012
Thu, May 3, 2012
Wed, May 2, 2012
Tue, May 1, 2012
Mon, April 30, 2012
Novogen Board Approves US$4 Million Investment In Marshall Edwards Rights Offering
Novogen Board Approves US$4 Million Investment In Marshall Edwards Rights Offering -- SYDNEY, May 8, 2012 /PRNewswire/ --
Novogen Board Approves US$4 Million Investment In Marshall Edwards Rights Offering
SYDNEY, May 8, 2012 /PRNewswire/ -- Novogen Limited (ASX: NRT Nasdaq: [ NVGN ]), announced today that following approval by its shareholders at an Extraordinary General Meeting held on 7 May, 2012, its Board of Directors has resolved to make a US$4 million investment in Marshall Edwards, Inc. ("MEI") under the MEI rights offering previously announced. The investment will be subject to availability of rights that have not been otherwise exercised by MEI or Novogen shareholders. On 20 April, 2012, Novogen distributed a dividend of 7,677,342 rights on a pro rata basis to its shareholders who have until 8 May, 2012 to exercise those rights.
Novogen's Chairman, William Rueckert, said, "We believe it is extremely important for Novogen to continue to support the MEI clinical development program because it represents the greatest opportunity for Novogen shareholders to see an increase in the value of their Novogen shares. As the majority shareholder of MEI, we felt it was essential for Novogen to take a leadership position in the rights offering and set an example that will encourage other shareholders to participate."
About Marshall Edwards
Marshall Edwards, Inc. is a San Diego-based oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The company's lead drug candidates, ME-143 and ME-344, have been shown in laboratory studies to interact with specific enzyme targets resulting in inhibition of tumour cell metabolism, a function critical for cancer cell survival. Marshall Edwards initiated a Phase I clinical trial of intravenous ME-143 in patients with solid refractory tumours in September, 2011 and plans to present safety and pharmacokinetic data from the trial at the American Society of Clinical Oncology Annual Meeting in June, 2012. The company received approval of its Investigational New Drug application for ME-344 in April, 2012 and initiated a Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumours shortly thereafter. For more information, please visit [ www.marshalledwardsinc.com ].
About Novogen Limited
Novogen Limited is an Australian biotechnology company based in Sydney, Australia. Novogen conducts research and development on oncology therapeutics through its subsidiary, Marshall Edwards, Inc., and is developing glucan technology through its subsidiary, Glycotex, Inc. More information on the Novogen group of companies can be found at [ www.novogen.com ].
SOURCE Novogen Limited
[ Back to top ] RELATED LINKS
[ http://www.novogen.com ]
[ http://www.marshalledwardsinc.com ]
